| Literature DB >> 32722122 |
Flavia Varano1, Daniela Catarzi1, Erica Vigiani1, Fabrizio Vincenzi2, Silvia Pasquini2, Katia Varani2, Vittoria Colotta1.
Abstract
The therapeutic use of A2AEntities:
Keywords: G protein-coupled receptors; adenosine A2A receptor ligands; adenosine receptors; thiazolo[5,4-d]pyrimidines
Year: 2020 PMID: 32722122 PMCID: PMC7465344 DOI: 10.3390/ph13080161
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Figure 1A2A AR antagonists progressed into clinical testing for the treatment of Parkinson’s disease (PD) and cancer.
Figure 2General structure of the designed 7-amino-2-(furan-2-yl)-thiazolo[5,4-d]pyrimidines.
Scheme 1Reagents and conditions. (a) n-BuOH, 200 °C MW, 20 min.
Scheme 2Reagents and conditions. (a) For 45–50: CH3CN, K2CO3, reflux, 14 h; for 51: CH3CN, Et3N, reflux, 24 h; (b) MeOH, NH2NH2·H2O, reflux, 2 h.
Scheme 3Reagents and conditions. (a) EtOH, benzaldehyde, reflux, 24 h; (b) CH3COCH3, K2CO3, rt, 12 h; (c) CH2Cl2/H2O, oxalic acid, reflux, 3 h.
Binding affinities (Ki) at hA1, hA2A, and hA3 ARs and potencies (IC50) at hA2B ARs.
| R5 | hA1AR a | hA2AAR b | hA2BAR c | hA3AR d | |
|---|---|---|---|---|---|
|
|
| 586 ± 37 | 594 ± 48 | >10,000 | >10,000 |
|
|
| 296 ± 22 | 64 ± 5 | >10,000 | >10,000 |
|
|
| 180 ± 15 | 58 ± 5 | 10,000 | 868 ± 82 |
|
|
| 1213 ± 114 | 237 ± 17 | >10,000 | 197 ± 16 |
|
|
| 2355 ± 213 | 326 ± 27 | >10,000 | 127 ± 15 |
|
|
| 2766 ± 249 | 137 ± 11 | >10,000 | 816 ± 74 |
|
|
| 345 ± 28 | 29 ± 3 | >10,000 | >10,000 |
|
|
| 638 ± 56 | 15.1 ± 1.3 | >10,000 | >10,000 |
|
|
| 4536 ± 312 | 279 ± 23 | >10,000 | 2679 ± 221 |
|
|
| 725 ± 67 | 187 ± 16 | >10,000 | >10,000 |
|
|
| 102 ± 9 | 8.62 ± 0.74 | >10,000 | >10,000 |
|
|
| 798 ± 72 | 92 ± 8 | >10,000 | >10,000 |
|
|
| 522 ± 47 | 37 ± 3 | >10,000 | >10,000 |
|
|
| 452 ± 38 | 18.3 ± 1.9 | >10,000 | 1492 ± 126 |
|
|
| 436 ± 36 | 10.8 ± 1.0 | >10,000 | >10,000 |
|
|
| >10,000 | 264 ± 24 | >10,000 (26%) | >10,000 (34%) |
|
|
| >10,000 | >10,000 | >10,000 (17%) | >10,000 (28%) |
|
|
| 524 ± 41 | 802 ± 73 | >10,000 | >10,000 |
|
|
| 365 ± 29 | 15.2 ± 1.7 | >10,000 | >10,000 |
|
|
| 152 ± 11 | 88 ± 9 | >10,000 | >10,000 |
|
|
| 247 ± 18 | 483 ± 34 | >10,000 | >10,000 |
|
| 188 ± 16 | 0.94 ± 0.07 | 51 ± 4 | 672 ± 51 | |
Data are expressed as means ± SEM. Affinity values obtained from the displacement of specific [3H]DPCPX a, [3H]ZM241383 b, or [125I]AB-MECA d binding to hA1ARs, hA2AARs, or A3ARs, respectively (n = 3–6). c Potency (IC50) in cAMP assays to hA2BARs. e Percentage of inhibition (I%) is determined at 10 μM concentration of the tested compounds. f Ref. 31.
Potency (IC50) of selected compounds on cyclic AMP assays in CHO cells expressing hA2A AR.
| Compounds | Potency | Intrinsic Activity | Pharmacological Behavior |
|---|---|---|---|
|
| 13.8 ± 1.2 | −44 ± 3 | Inverse agonist |
|
| 7.42 ± 0.68 | −52 ± 4 | Inverse agonist |
|
| 15.2 ± 1.3 | −51 ± 5 | Inverse agonist |
|
| 9.42 ± 0.87 | −67 ± 5 | Inverse agonist |
|
| 14.8 ± 1.4 | −64 ± 4 | Inverse agonist |
|
| 1.42 ± 0.11 | −48 ± 4 | Inverse agonist |
Data are expressed as means ± SEM.
Figure 3Bioavailability radars for the analyzed compounds, from the SwissADME web tool. LIPO = lipophilicity (XLOGP3 between −0.7 and 5.0); SIZE (molecular weight between 150 and 500 g/mol); POLAR = polarity (TPSA between 20 and 130 Å2); INSOLU = solubility (log S not higher than 6); INSATU = saturation (fraction of carbons in the sp3 hybridization not less than 0.25); FLEX = flexibility (no more than nine rotatable bonds).
Figure 4Predicted BOILED-Egg diagram of the analyzed compounds, from the SwissADME web tool.